- Home
- ABL vs NEO Comparison
ABL vs NEO Comparison
Compare ABL & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- NEO
- Stock Information
- Founded
- ABL 2004
- NEO 2001
- Country
- ABL United States
- NEO United States
- Employees
- ABL N/A
- NEO N/A
- Industry
- ABL Investment Managers
- NEO Precision Instruments
- Sector
- ABL Finance
- NEO Health Care
- Exchange
- ABL Nasdaq
- NEO Nasdaq
- Market Cap
- ABL 853.6M
- NEO 965.2M
- IPO Year
- ABL N/A
- NEO 1999
- Fundamental
- Price
- ABL $7.73
- NEO $7.28
- Analyst Decision
- ABL Strong Buy
- NEO Buy
- Analyst Count
- ABL 4
- NEO 9
- Target Price
- ABL $13.63
- NEO $13.31
- AVG Volume (30 Days)
- ABL 453.4K
- NEO 1.7M
- Earning Date
- ABL 05-08-2025
- NEO 04-29-2025
- Dividend Yield
- ABL N/A
- NEO N/A
- EPS Growth
- ABL N/A
- NEO N/A
- EPS
- ABL N/A
- NEO N/A
- Revenue
- ABL $134,575,948.00
- NEO $672,361,000.00
- Revenue This Year
- ABL $65.34
- NEO $13.95
- Revenue Next Year
- ABL $25.72
- NEO $11.16
- P/E Ratio
- ABL N/A
- NEO N/A
- Revenue Growth
- ABL 73.39
- NEO 10.10
- 52 Week Low
- ABL $6.34
- NEO $6.08
- 52 Week High
- ABL $12.40
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- ABL 34.93
- NEO 38.30
- Support Level
- ABL $7.90
- NEO $7.28
- Resistance Level
- ABL $8.50
- NEO $7.63
- Average True Range (ATR)
- ABL 0.28
- NEO 0.37
- MACD
- ABL -0.15
- NEO -0.00
- Stochastic Oscillator
- ABL 9.49
- NEO 12.42
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.